Wellington Management Group LLP Sells 5,478 Shares of Intuitive Surgical, Inc. $ISRG

Wellington Management Group LLP lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,151,229 shares of the medical equipment provider’s stock after selling 5,478 shares during the quarter. Wellington Management Group LLP’s holdings in Intuitive Surgical were worth $1,409,324,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Kilter Group LLC purchased a new stake in Intuitive Surgical in the second quarter worth approximately $27,000. Greykasell Wealth Strategies Inc. bought a new stake in shares of Intuitive Surgical in the 3rd quarter worth approximately $27,000. Caitlin John LLC bought a new stake in shares of Intuitive Surgical in the 3rd quarter worth approximately $30,000. Guerra Advisors Inc purchased a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $37,000. Finally, Riggs Asset Managment Co. Inc. grew its holdings in shares of Intuitive Surgical by 84.2% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 32 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $472.16 on Friday. The firm has a market cap of $167.68 billion, a P/E ratio of 59.84, a P/E/G ratio of 3.70 and a beta of 1.66. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $603.88. The business’s 50 day moving average price is $513.26 and its 200-day moving average price is $512.40.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The company had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the company earned $2.21 earnings per share. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ISRG. Sanford C. Bernstein boosted their price target on shares of Intuitive Surgical from $740.00 to $750.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Barclays set a $712.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a report on Monday, January 26th. Argus dropped their target price on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. The Goldman Sachs Group restated a “buy” rating and set a $714.00 price target on shares of Intuitive Surgical in a research report on Friday, January 9th. Finally, Royal Bank Of Canada boosted their price objective on Intuitive Surgical from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $615.86.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Insider Activity at Intuitive Surgical

In other news, SVP Mark Brosius sold 2,362 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $498.68, for a total value of $1,177,882.16. Following the completion of the sale, the senior vice president directly owned 3,554 shares of the company’s stock, valued at approximately $1,772,308.72. This trade represents a 39.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gary S. Guthart sold 24,500 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total transaction of $12,987,450.00. Following the sale, the director directly owned 3,694 shares in the company, valued at $1,958,189.40. The trade was a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,407 shares of company stock valued at $17,534,067 over the last quarter. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.